Use Tempus’ multimodal data to help identify, select and refine biomarkers for your clinical trial.
8M+
de-identified research records
1.5M+
records with matched clinical data linked with genomic information
~300K
records with whole transcriptome profiles
Tempus applies an established, design-controlled, and validated platform approach with the goal of reducing development time and complexity for companion diagnostic approval.
Leverage Tempus’ network to help identify potentially eligible patients for clinical trial enrollment and introduce your therapy and companion diagnostic to market following FDA submission and approval.
6.5K+
oncologists rely on Tempus as their precision medicine partner
95%
of the top 20 pharma oncology companies*
*based on publicly available 2020 oncology segment revenue
200+
biopharma partnerships
With extensive in-house regulatory expertise, Tempus’ approach to CDx development and approval is strategically designed to save time, reduce complexity and improve the probability of success. Tempus offers a wide range of NGS tests to support pharma, including DNA and RNA tissue-based assays to support IDE studies.
Tempus Explore
Tempus bioinformatics experts help you answer your oncology research questions and meet your research objectives efficiently.
Multi-omics
Empowers pharma partners with access to bioinformatics experts to help answer research questions comprehensively and reach objectives efficiently.
NGS & Multi-omics
Leverage Tempus’ CAP-accredited, CLIA-certified robotic sequencing labs for NGS diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing solutions.
TIME, Connect, Aware
Tempus’ smart clinical trial matching tools save time and maximize the probability of technical success.
Tempus’ regulatory team is closely involved with CDx projects to develop and execute robust regulatory strategies.
Sponsored Testing
Address barriers to testing specific cohorts of patients to identify appropriate patients for targeted therapies.
Tempus Explore
Tempus bioinformatics experts help you answer your oncology research questions and meet your research objectives efficiently.
Multi-omics
Empowers pharma partners with access to bioinformatics experts to help answer research questions comprehensively and reach objectives efficiently.
NGS & Multi-omics
Leverage Tempus’ CAP-accredited, CLIA-certified robotic sequencing labs for NGS diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing solutions.
TIME, Connect, Aware
Tempus’ smart clinical trial matching tools save time and maximize the probability of technical success.
Additional CDx claims can be added without building a new platform
Reduces the need to work with multiple vendors across your pipeline
Generates data to help identify subpopulations and develop more targeted therapies
In a recent webinar hosted by Tempus, industry leaders from healthcare and life sciences gathered to explore current and emerging applications of transcriptomic data in oncology.
Read more
Tempus leaders Chris Scotto DiVetta, SVP & General Manager of AI Applications, and Jonathan Ozeran, VP of Generative AI, discuss how the Tempus platform leverages AI and machine learning to support standard of care practices, helping providers adhere to clinical guidelines and drive insights that help refine clinical trial strategy.
Read more
This white paper explores the evolving role of organoids in oncology R&D, highlighting their potential as predictive preclinical models and their ability to reduce translational risk. Download for a comprehensive overview of the scientific landscape, key adoption barriers, emerging innovations, and how pharma companies leverage organoids to accelerate precision medicine.
Read more
This Q&A article features a discussion between Dr. Allan Espinosa of Arizona Oncology and Dr. Ezra Cohen, Chief Medical Officer at Tempus, exploring the practical application of Tempus’ tumor-naive and tumor-informed MRD and IO treatment monitoring portfolio in clinical practice.
Read more
Tim Hagerty, Ph.D, VP, Life Science Strategy at Tempus, discusses Tempus Loop, a platform aimed at enhancing target identification and validation by connecting real-world data with patient-derived organoids. He explains how this integrated approach overcomes limitations in traditional methods and its potential to accelerate preclinical development in oncology.
Read more
Discover how Tempus developed and deployed the Immune Profile Score (IPS)—a powerful algorithm that provides prognostic insights into patient outcomes following treatment with immune checkpoint inhibitors (ICIs)—in ~18 months. This case study highlights the AI-driven methodology, real-world validation, and the impact of IPS in precision oncology.
Read more
Discover how Tempus is equipping researchers with innovative AI solutions to fully leverage the potential of multimodal data. Gain insights from a panel of leaders across healthcare and life sciences as they discuss the impact of these advanced tools on delivering insights with speed.
Watch replay
Ryan Fukushima, Chief Operating Officer at Tempus, discusses how cutting-edge tools are helping biotechs streamline clinical trials, optimize patient selection, and improve decision-making, even amidst challenging market conditions.
Read more
Explore the capabilities of the Tempus platform, where cutting-edge diagnostics meet actionable data insights to enhance precision medicine.
Watch replayTempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, announced that the Centers for Medicare & Medicaid Services (CMS) has granted Advanced Diagnostic Laboratory Test (ADLT) status for Tempus’ next-generation sequencing assay.
Read press releaseThe information on this page is intended for life sciences companies and focuses on research and development applications.
This is the future of healthcare.